Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | DHFR | P00374 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SCD | O00767 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442802 | 1.00 | POLB (0.69) | POLBDHFRLTA4HEPHX2TAAR1 | |
| SCHEMBL31063674 | 0.83 | POLB (0.51) | POLBDHFREPHX2TSHRSCD | |
| SCHEMBL34467558 | 0.83 | POLB (0.51) | POLBDHFRLTA4HEPHX2TAAR1 | |
| SCHEMBL3138985 | 0.82 | POLB (1.00) | POLBLTA4HEPHX2TSHRMEN1 | |
| SCHEMBL3144357 | 0.81 | EPHX2 (0.54) | POLBLTA4HEPHX2TAAR1TSHR | |
| SCHEMBL16060028 | 0.79 | MTNR1A (0.47) | POLBDHFRTAAR1SCDIDO1 | |
| SCHEMBL29442801 | 0.78 | LMNA (0.56) | POLBEPHX2TSHRMEN1KMT2A | |
| SCHEMBL965932 | 0.78 | EPHX2 (0.54) | POLBEPHX2TAAR1TSHRSCD | |
| SCHEMBL234063 | 0.78 | LMNA (0.56) | POLBEPHX2TSHRMEN1KMT2A | |
| SCHEMBL34467564 | 0.78 | EPHX2 (0.54) | POLBDHFREPHX2TAAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| CN-118084800-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084801-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112312913-B | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-22 | — | — | US | disclosed |
| CN-114174273-A | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3941908-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-112312913-A | Compounds and uses thereof | 优曼尼蒂治疗公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-3768269-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2020198026-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198026-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2019183587-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019183587-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20160046616-A1 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2014145642-A9 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-11-13 | — | — | WO | disclosed |
| WO-2014145642-A2 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8580763-B2 | 2, 6-dinitrogen-containing substituted purine derivatives, the preparation and uses thereof | ZHANGGUI WU (CN) | 2013-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046616-A1 | NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY | NFE2L2, KEAP1, GSTK1 | POLB 932/4885DHFR 1216/4885LTA4H 3241/4885 |
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | POLB 3273/4885DHFR 85/4885LTA4H 1300/4885 |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | POLB 3788/4885DHFR 174/4885LTA4H 521/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | POLB 3788/4885DHFR 174/4885LTA4H 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.